Advance in search for new Clostridioides difficile vaccine

October 25, 2019

Scientists have made a breakthrough in the hunt for a new vaccine for killer hospital bug Clostridioides difficile (C. diff).

University of Exeter researchers first identified a gene in C. diff responsible for producing a protein that aids in binding the bacteria to the gut of its victims.

In collaboration with researchers at Paris-SUD University, they then showed that mice vaccinated with this protein generated specific antibodies to the protein - and that C. diff that did not produce this protein were less able to attach to the gut.

C. diff bacteria must bind to the gut to produce the toxin that causes illness, and the Exeter team are hopeful that vaccination against attachment will be effective in humans.

No C. diff vaccine is currently in widespread use. Some toxin-based vaccines are currently in clinical trials, but the Exeter research offers a promising new approach. C. diff infections, which commonly occur in people who have recently taken antibiotics, can cause severe illness and results in thousands of deaths each year, especially among the elderly and other vulnerable groups.

"Infection by C. diff often occurs when the natural gut bacteria are disrupted by antibiotics," said Dr Stephen Michell, of the University of Exeter.

"With other bacteria missing, C. diff can attach to the gut and release a toxin that causes symptoms including diarrhoea.

"We identified a gene - CD0873 - that generates a protein that helps C. diff bind to the gut.

"This binding is thought to be key for C. diff infections, so if we can prevent adhesion of bacteria then there's a real possibility of preventing this disease."

The researchers immunised mice with the CD0873 protein in isolation (not as part of a C. diff bacterium) and found a "strong" immune response.

When subsequently exposed to C. diff, these immunised mice were unaffected while non-immunised mice fell ill and lost about 10 percent of their body weight on average.

The research began as a collaboration between the University of Exeter, Novartis and the University of Nottingham, and this latest collaborative study involved the University of Bath and University Paris-Sud.

Both the universities of Bath and Exeter are part of the GW4 Alliance, a collaborative research alliance of research-intensive and innovative universities in the South West and Wales.

Scientists at University Paris-Sud conducted the experiments that showed that mice develop antibodies when immunised with the CD0873 protein.

The Bath researchers mapped the 3D molecular structure of CD0873 at high resolution using the high-brightness X-ray beam at the UK's state-of-the-art facility, Diamond Light Source at Didcot in Oxfordshire providing more information on its function.

The new paper, published in the Journal of Biological Chemistry, is entitled: "Molecular features of lipoprotein CD0873: A potential vaccine against the human pathogen Clostridioides difficile."

A study published in 2015 said C diff caused almost half a million infections in the US in a year, directly leading to 15,000 deaths.

Whilst several C. diff toxin-targeted vaccines are currently in clinical trials, in 2017, pharmaceutical company Sanofi scrapped its efforts to find a toxin-based C. diff vaccine after many years, citing a low probability of success.

This alternative, adhesion-targeting vaccine identified by this important research may be a key new approach to disease control.

Dr Ray Sheridan, a consultant physician at the Royal Devon & Exeter Hospital, said: "A vaccine that stops the C. diff sticking to the gut wall and so stops it making the gut its new home would then stop the bug being able to cause diarrhoea or infection.

"This would need to go through clinical trials but if it worked it would potentially prevent C. diff infection altogether.

"Our current treatments rely on using more antibiotics, and we need to move away from that approach as antibiotics are one of the main causes of the C. diff problem in the first place by interfering with natural gut flora of bacteria."
-end-


University of Exeter

Related Bacteria Articles from Brightsurf:

Siblings can also differ from one another in bacteria
A research team from the University of Tübingen and the German Center for Infection Research (DZIF) is investigating how pathogens influence the immune response of their host with genetic variation.

How bacteria fertilize soya
Soya and clover have their very own fertiliser factories in their roots, where bacteria manufacture ammonium, which is crucial for plant growth.

Bacteria might help other bacteria to tolerate antibiotics better
A new paper by the Dynamical Systems Biology lab at UPF shows that the response by bacteria to antibiotics may depend on other species of bacteria they live with, in such a way that some bacteria may make others more tolerant to antibiotics.

Two-faced bacteria
The gut microbiome, which is a collection of numerous beneficial bacteria species, is key to our overall well-being and good health.

Microcensus in bacteria
Bacillus subtilis can determine proportions of different groups within a mixed population.

Right beneath the skin we all have the same bacteria
In the dermis skin layer, the same bacteria are found across age and gender.

Bacteria must be 'stressed out' to divide
Bacterial cell division is controlled by both enzymatic activity and mechanical forces, which work together to control its timing and location, a new study from EPFL finds.

How bees live with bacteria
More than 90 percent of all bee species are not organized in colonies, but fight their way through life alone.

The bacteria building your baby
Australian researchers have laid to rest a longstanding controversy: is the womb sterile?

Hopping bacteria
Scientists have long known that key models of bacterial movement in real-world conditions are flawed.

Read More: Bacteria News and Bacteria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.